🔬 Introduction
Researchers at Mashhad University of Medical Sciences have developed an innovative dual-delivery nanoplatform designed to enhance the effectiveness of chemotherapy in breast cancer. This novel Janus nanoparticle, combining AZIF-8 and liposomes, offers targeted, simultaneous delivery of both hydrophilic and hydrophobic drugs.
🧪What Makes This Nanoparticle Special?
- Janus Design: Two functional faces—AZIF-8 loaded with doxorubicin (DOX) and liposomes containing mitoxantrone (MTX).
- Microfluidic Synthesis: Ensures precise control over size and composition.
- Dual Targeting:
- 4T1 cancer cell membrane coating (biomimetic camouflage)
- AS1411 aptamer conjugation (targets nucleolin on cancer cells)
🧫 Key Findings (In Vitro & In Vivo)
- ✔️ High cellular uptake in 4T1 cells (cancer-specific)
- ✔️ Significant cytotoxicity to tumor cells with minimal effects on healthy tissue
- ✔️ Strong suppression of tumor growth in mice
- ✔️ No observable damage to vital organs
📌 Conclusion
The Liposome/AZIF-8 Janus@Membrane-Aptamer formulation offers a safe, efficient strategy to overcome drug resistance and improve chemotherapy outcomes in breast cancer — a promising step forward in precision nanomedicine.
📄 Full Article Reference
Title: LiposomeAZIF-8 Janus nanoplatforms for codelivery of paclitaxel/siRNA and modulation of tumor microenvironment
Journal: Materials Today Bio, 2023
DOI: https://doi.org/10.1016/j.mtbio.2023.100595
